

Now Available for Antimicrobial Susceptibility Testing, ORBACTIV® (Oritavancin) on FDA-Cleared Microbroth Dilution Susceptibility Plates
New product offers more testing options for microbiology labs and more targeted therapy for patients



OAKWOOD VILLAGE, Ohio--The new antimicrobial oritavancin represents one of the latest treatment options for skin infections and is now available on FDA-cleared microbroth dilution susceptibility plates, giving microbiology laboratories the means for susceptibility testing of fastidious and non-fastidious gram positive organisms that cause skin infections in adults.

Recognized for offering one of the largest and most up-to-date selections of FDA-cleared antimicrobials for susceptibility testing, the Thermo Scientific Sensititre ID/AST System is now the first to offer oritavancin on IVD-labeled microbroth dilution susceptibility plates. Oritavancin is currently available in the U.S. on Sensititre custom plates, and will be featured on additional standard plates in the future. Testing can be performed manually, as well as using the Sensititre Vizion Digital MIC Viewing System, Sensititre OptiRead Automated

Fluorometric Plate Reading System, or the fully automated Sensititre ARIS 2X System.

According to Mario Gualano, president, Thermo Fisher Scientific Microbiology, “The development of new antimicrobial compounds is critical to combating emerging resistance as we begin to see traditional treatments losing their effectiveness. By partnering with pharmaceutical companies to support new drug development, we are able to make these compounds widely available for testing upon clearance, and provide clinicians with another option in making decisions for the effective treatment of patients.”

The Sensititre System utilizes true minimum inhibitory concentration (MIC) results, which are essential to fighting antimicrobial resistance, providing greater sensitivity for better resistance tracking. True MIC results are also the best measure of antibacterial effect, which can assist with therapeutic choices, and promote overall better patient care.

ORBACTIV (oritavancin, The Medicines Company) for injection is approved by the FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by the following isolates: *Staphylococcus aureus* (including methicillin-susceptible and methicillin-resistant isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Streptococcus anginosus* group (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), and *Enterococcus faecalis* (vancomycin-susceptible isolates only).

More information on the Thermo Scientific Sensititre System can be found [here](#), by visiting www.thermoscientific.com, or by contacting microbiology@thermofisher.com.

“ORBACTIV” is a registered trademark of The Medicines Company. All other trademarks are the property of Thermo Fisher Scientific.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of \$17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Contacts

Thermo Fisher Scientific
Carlene Graham, 800-971-8909 x3224109
carlene.graham@thermofisher.com

THERMO FISHER SCIENTIFIC



<https://thermofisher.mediaroom.com/press-releases?item=122917>